KR102745894B1 - Cfdna를 이용한 방광암 진단방법 - Google Patents

Cfdna를 이용한 방광암 진단방법 Download PDF

Info

Publication number
KR102745894B1
KR102745894B1 KR1020200041227A KR20200041227A KR102745894B1 KR 102745894 B1 KR102745894 B1 KR 102745894B1 KR 1020200041227 A KR1020200041227 A KR 1020200041227A KR 20200041227 A KR20200041227 A KR 20200041227A KR 102745894 B1 KR102745894 B1 KR 102745894B1
Authority
KR
South Korea
Prior art keywords
cfdna
marker
probe
cancer
positively charged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020200041227A
Other languages
English (en)
Korean (ko)
Other versions
KR20200117911A (ko
Inventor
조영남
Original Assignee
주식회사 제놉시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 제놉시 filed Critical 주식회사 제놉시
Publication of KR20200117911A publication Critical patent/KR20200117911A/ko
Application granted granted Critical
Publication of KR102745894B1 publication Critical patent/KR102745894B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2527/00—Reactions demanding special reaction conditions
    • C12Q2527/101—Temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/125—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being enzymatic, i.e. proteins, and non proteins, such as nucleic acid with enzymatic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/131—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a member of a cognate binding pair, i.e. extends to antibodies, haptens, avidin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/155—Particles of a defined size, e.g. nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020200041227A 2019-04-05 2020-04-03 Cfdna를 이용한 방광암 진단방법 Active KR102745894B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020190039974 2019-04-05
KR20190039974 2019-04-05
KR20190157368 2019-11-29
KR1020190157368 2019-11-29

Publications (2)

Publication Number Publication Date
KR20200117911A KR20200117911A (ko) 2020-10-14
KR102745894B1 true KR102745894B1 (ko) 2024-12-23

Family

ID=72666861

Family Applications (10)

Application Number Title Priority Date Filing Date
KR1020200041227A Active KR102745894B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 방광암 진단방법
KR1020200041228A Active KR102526906B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 유방암 진단방법
KR1020200041230A Active KR102526913B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 대장암 진단방법
KR1020200041233A Active KR102745900B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 담도암 진단방법
KR1020200041226A Active KR102745889B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 갑상선암 진단방법
KR1020200041223A Active KR102372425B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 폐암 진단방법
KR1020200041243A Active KR102745906B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 췌장암 진단방법
KR1020200041245A Active KR102745908B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 암 진단방법
KR1020200041220A Active KR102745852B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 전립선암 진단방법
KR1020200041239A Active KR102526916B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 위암 진단방법

Family Applications After (9)

Application Number Title Priority Date Filing Date
KR1020200041228A Active KR102526906B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 유방암 진단방법
KR1020200041230A Active KR102526913B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 대장암 진단방법
KR1020200041233A Active KR102745900B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 담도암 진단방법
KR1020200041226A Active KR102745889B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 갑상선암 진단방법
KR1020200041223A Active KR102372425B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 폐암 진단방법
KR1020200041243A Active KR102745906B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 췌장암 진단방법
KR1020200041245A Active KR102745908B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 암 진단방법
KR1020200041220A Active KR102745852B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 전립선암 진단방법
KR1020200041239A Active KR102526916B1 (ko) 2019-04-05 2020-04-03 Cfdna를 이용한 위암 진단방법

Country Status (7)

Country Link
US (1) US20220170108A1 (cg-RX-API-DMAC7.html)
EP (1) EP3950962A4 (cg-RX-API-DMAC7.html)
JP (2) JP7782835B2 (cg-RX-API-DMAC7.html)
KR (10) KR102745894B1 (cg-RX-API-DMAC7.html)
CN (1) CN113677808A (cg-RX-API-DMAC7.html)
TW (1) TW202104598A (cg-RX-API-DMAC7.html)
WO (1) WO2020204674A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020378435B2 (en) * 2019-11-06 2026-07-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
WO2022203093A1 (ko) * 2021-03-22 2022-09-29 이원다이애그노믹스(주) 암 발생여부를 진단 또는 예측하는 방법
US11783912B2 (en) 2021-05-05 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
CN113718031B (zh) * 2021-08-17 2022-05-20 浙江大学医学院附属妇产科医院 一种卵巢癌早期诊断组合物的建立
CN116219012A (zh) * 2022-12-15 2023-06-06 华中科技大学同济医学院附属同济医院 基于血浆cfDNA片段分布特征预测宫颈癌新辅助化疗效果或复发高危分类的系统及方法
KR20250030880A (ko) 2023-08-25 2025-03-05 경상국립대학교병원 폐암 치료 예후 예측을 위한 정보제공방법 및 폐암 치료 예후 예측용 조성물
KR20250074714A (ko) * 2023-11-15 2025-05-28 주식회사 진캐스트 Rna를 이용한 폐암 변이 유전자의 대규모 다중 검출 방법 및 이를 이용한 폐암 변이 유전자의 대규모 다중 검출 키트
KR20250090657A (ko) * 2023-12-13 2025-06-20 연세대학교 산학협력단 높은 sfrp4의 발현을 보이는 암의 치료방법
WO2025213150A1 (en) * 2024-04-06 2025-10-09 Precede Biosciences, Inc. Methods, kits and systems for measuring psa and psma expression and methods for treating cancer based on same
CN118497344A (zh) * 2024-05-11 2024-08-16 青岛可立生物医药有限公司 用于结直肠癌诊断及分型的生物标志物及筛选方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778872A2 (en) * 2004-08-11 2007-05-02 The Cleveland Clinic Foundation Method of detecting thyroid cancer
US9315802B2 (en) * 2009-12-30 2016-04-19 Quest Diagnostics Investments Incorporated RNA isolation from soluble urine fractions
CA2965528A1 (en) * 2014-11-14 2016-05-19 Liquid Genomics, Inc. Use of circulating cell-free rna for diagnosis and/or monitoring cancer
US20160265064A1 (en) * 2015-03-11 2016-09-15 The Governing Council Of The University Of Toronto Electrochemical clamp assay
SMT202200062T1 (it) * 2015-03-12 2022-03-21 Janssen Pharmaceutica Nv Marcatori di mrna a base di sangue intero per la previsione del cancro della prostata e metodi di rilevazione degli stessi
KR101751962B1 (ko) 2015-04-30 2017-06-30 주식회사 넥스바이오 세포-유리형 dna의 위암 진단 용도
KR101701618B1 (ko) * 2015-06-23 2017-02-13 국립암센터 전도성 고분자를 이용한 세포 유리 dna 검출용 구조체 및 이의 용도
US11149299B2 (en) * 2015-06-25 2021-10-19 Ramesh Vallabhaneni Method and system for multiplex profiling of chromosomes in biological samples using target-specific DNA probes
KR20170124683A (ko) * 2016-05-02 2017-11-13 연세대학교 산학협력단 담도암 진단용 신규 바이오마커로서의 융합 유전자 및 융합 단백질
KR101925125B1 (ko) 2016-06-16 2018-12-04 울산대학교 산학협력단 Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
KR101818352B1 (ko) * 2016-06-30 2018-01-15 충북대학교 산학협력단 방광암의 진단 및 예후 예측용 바이오 마커 및 그의 용도
KR101980819B1 (ko) * 2016-12-23 2019-05-21 주식회사 제놉시 자성 나노 입자가 탑재된 전도성 고분자 및 양이온성 고분자를 포함하는 세포-유리(cell-free) DNA 검출 및 회수용 자성 나노 구조체
EP3358020B1 (en) * 2017-01-05 2021-05-19 Biodesix, Inc. Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole blood
KR20200003917A (ko) * 2017-05-10 2020-01-10 난토믹스, 엘엘씨 암의 검출, 예측, 및 모니터링을 위한 순환 rna(circulating rna for detection, prediction, and monitoring of cancer)
CN107164543A (zh) * 2017-06-16 2017-09-15 上海长海医院 Kras 作为胰腺癌中生物标志物的用途
CN112236529B (zh) * 2018-06-01 2025-01-03 健诺心理股份有限公司 检测不稳定的无细胞dna的方法及使用其的装置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Sci Rep, 8: 14707 (2018.10.02.)*
Theranostics, 8(2): 399-409 (2018.01.01.)*

Also Published As

Publication number Publication date
KR20200117912A (ko) 2020-10-14
CN113677808A (zh) 2021-11-19
KR102745889B1 (ko) 2024-12-23
EP3950962A4 (en) 2023-01-11
KR20200117910A (ko) 2020-10-14
WO2020204674A3 (ko) 2020-12-17
KR20200117914A (ko) 2020-10-14
KR20200117913A (ko) 2020-10-14
US20220170108A1 (en) 2022-06-02
KR20200117909A (ko) 2020-10-14
KR20200117916A (ko) 2020-10-14
KR102372425B1 (ko) 2022-03-10
JP2026021394A (ja) 2026-02-10
KR102745852B1 (ko) 2024-12-23
EP3950962A2 (en) 2022-02-09
KR102745906B1 (ko) 2024-12-23
KR20200117917A (ko) 2020-10-14
JP7782835B2 (ja) 2025-12-09
KR102745900B1 (ko) 2024-12-23
KR102526916B1 (ko) 2023-05-02
TW202104598A (zh) 2021-02-01
WO2020204674A2 (ko) 2020-10-08
KR102526906B1 (ko) 2023-05-02
KR102526913B1 (ko) 2023-05-02
KR20200117907A (ko) 2020-10-14
KR20200117915A (ko) 2020-10-14
JP2022528278A (ja) 2022-06-09
KR20200117911A (ko) 2020-10-14
KR102745908B1 (ko) 2024-12-23

Similar Documents

Publication Publication Date Title
KR102745906B1 (ko) Cfdna를 이용한 췌장암 진단방법
Kowalczyk Trends and perspectives in DNA biosensors as diagnostic devices
JP2022528278A5 (cg-RX-API-DMAC7.html)
Dolezal et al. Elevated levels of glycosylphosphatidylinositol (GPI) anchored proteins in plasma from human cancers detected by C. septicum alpha toxin
CN107980061A (zh) 使用导电聚合物的游离dna捕获平台以及该平台的应用
US11384126B2 (en) Compositions and methods for inhibiting DHHC-type palmitoyltransferases for cancer treatment
JP7569110B2 (ja) 不安定セルフリーdnaを検出する方法およびそれを使用するデバイス
WO2014062845A1 (en) Compositions and methods for detecting sessile serrated adenomas/polyps
Oguzhan Caglayan Electrochemical aptasensors for early cancer diagnosis: a review
CN111781180A (zh) 一种用于检测外泌体的dna分子机器
Guliy et al. Heat shock proteins as biosensor instruments for cancer detection
US20050003405A1 (en) Treatment and diagnostics of cancer
CN116162706A (zh) 一种用于食管鳞癌诊断的外泌体lncRNA标志物组及其应用
Koushanpour et al. Molecular biointerfacing of electrochemical aptamer-based sensors for breast cancer biomarkers
Chen et al. Urine Biomarkers for Prostate Cancer Detection

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20200403

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240620

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241217

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241218

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241219

End annual number: 3

Start annual number: 1

PG1601 Publication of registration